For the quarter ending 2025-09-30, SPRO made $5,442,000 in revenue. -$7,382,000 in net income. Net profit margin of -135.65%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Total revenues | 5,442,000 | 14,189,000 | 5,874,000 | 11,502,666.667 |
| Research and development | 8,597,000 | 10,672,000 | 13,606,000 | 23,297,666.667 |
| General and administrative | 4,174,000 | 5,878,000 | 6,824,000 | 6,168,666.667 |
| Impairment charges | 587,000 | - | - | - |
| Restructuring | 0 | 83,000 | 175,000 | 219,250 |
| Total operating expenses | 13,358,000 | 16,633,000 | 20,605,000 | 29,758,666.667 |
| Loss from operations | -7,916,000 | -2,444,000 | -14,731,000 | -18,256,000 |
| Interest income | 532,000 | 740,000 | - | 1,184,333.333 |
| Other income (expense), net | 2,000 | 4,000 | - | 28,666.667 |
| Total other income, net | 534,000 | 744,000 | - | 1,213,000 |
| Net loss before income taxes | -7,382,000 | - | - | -17,043,000 |
| Income tax benefit | 0 | - | - | - |
| Net loss and comprehensive loss | -7,382,000 | -1,700,000 | - | -17,139,666.667 |
| Earnings per share, basic | -0.13 | -0.03 | -0.25 | -0.317 |
| Earnings per share, diluted | -0.13 | -0.03 | -0.25 | -0.317 |
| Weighted average number of shares outstanding, basic | 56,280,844 | 56,026,767 | 55,376,188 | -28,981.667 |
| Weighted average number of shares outstanding, diluted | 56,280,844 | 56,026,767 | 55,376,188 | -28,981.667 |
Spero Therapeutics, Inc. (SPRO)
Spero Therapeutics, Inc. (SPRO)